GYRE Gyre Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GYRE

Price (delayed)

$6.16

Market cap

$597.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$561.02M

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 35

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic ...

Highlights
Gyre Therapeutics's debt has decreased by 48% YoY and by 12% QoQ
GYRE's revenue is up by 16% year-on-year
The company's equity rose by 49% YoY but it fell by 4.5% QoQ
GYRE's quick ratio is up by 40% year-on-year but it is down by 21% since the previous quarter
GYRE's EPS has dropped by 200% year-on-year
The net income has plunged by 188% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of GYRE

GYRE stock price

How has the Gyre Therapeutics stock price performed over time
Intraday
8.26%
1 week
7.32%
1 month
-22.22%
1 year
-28.21%
YTD
-12.75%
QTD
-11.62%

Financial performance

How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$117.05M
Gross profit
$111.3M
Operating income
-$141,000
Net income
-$6.36M
Gross margin
95.1%
Net margin
-5.4%
The net income has plunged by 188% YoY
Gyre Therapeutics's net margin has shrunk by 175% YoY
GYRE's operating income has dropped by 101% year-on-year and by 101% since the previous quarter
The company's operating margin has shrunk by 101% QoQ and by 101% YoY

Price vs fundamentals

How does GYRE's price correlate with its fundamentals

Growth

What is Gyre Therapeutics's growth rate over time

Valuation

What is Gyre Therapeutics stock price valuation
GYRE P/E details
P/E
N/A
P/B
5.9
P/S
4.81
EV/EBIT
N/A
EV/EBITDA
422.13
EV/Sales
4.79
GYRE's EPS has dropped by 200% year-on-year
The company's equity rose by 49% YoY but it fell by 4.5% QoQ
GYRE's P/B is 28% below its 5-year quarterly average of 7.6 and 21% below its last 4 quarters average of 6.9
The stock's price to sales (P/S) is 46% less than its 5-year quarterly average of 8.2 and 25% less than its last 4 quarters average of 5.9
GYRE's revenue is up by 16% year-on-year

Efficiency

How efficient is Gyre Therapeutics business performance
Gyre Therapeutics's ROA has plunged by 169% YoY
The ROE has dropped by 155% year-on-year
GYRE's ROIC has plunged by 122% from the previous quarter and by 118% YoY
GYRE's return on sales has dropped by 122% since the previous quarter and by 117% year-on-year

Dividends

What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Gyre Therapeutics financials performed over time
GYRE's quick ratio is up by 40% year-on-year but it is down by 21% since the previous quarter
GYRE's current ratio is up by 29% year-on-year but it is down by 17% since the previous quarter
Gyre Therapeutics's debt is 99% lower than its equity
Gyre Therapeutics's debt to equity has shrunk by 50% YoY
The company's equity rose by 49% YoY but it fell by 4.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.